- Home
- INSI vs FENC Comparison
INSI vs FENC Comparison
Compare INSI & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSI
- FENC
- Stock Information
- Founded
- INSI 1971
- FENC 1996
- Country
- INSI United States
- FENC United States
- Employees
- INSI N/A
- FENC N/A
- Industry
- INSI Investment Managers
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INSI Finance
- FENC Health Care
- Exchange
- INSI Nasdaq
- FENC Nasdaq
- Market Cap
- INSI 183.7M
- FENC 156.9M
- IPO Year
- INSI N/A
- FENC 2001
- Fundamental
- Price
- INSI $16.62
- FENC $6.23
- Analyst Decision
- INSI
- FENC Strong Buy
- Analyst Count
- INSI 0
- FENC 2
- Target Price
- INSI N/A
- FENC $14.00
- AVG Volume (30 Days)
- INSI 22.0K
- FENC 64.0K
- Earning Date
- INSI 01-01-0001
- FENC 03-20-2025
- Dividend Yield
- INSI 4.90%
- FENC N/A
- EPS Growth
- INSI N/A
- FENC N/A
- EPS
- INSI N/A
- FENC N/A
- Revenue
- INSI N/A
- FENC $49,348,000.00
- Revenue This Year
- INSI N/A
- FENC $170.43
- Revenue Next Year
- INSI N/A
- FENC $6.70
- P/E Ratio
- INSI N/A
- FENC N/A
- Revenue Growth
- INSI N/A
- FENC 278.09
- 52 Week Low
- INSI $14.28
- FENC $3.96
- 52 Week High
- INSI $16.40
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- INSI 33.80
- FENC 59.87
- Support Level
- INSI $16.96
- FENC $5.45
- Resistance Level
- INSI $17.07
- FENC $6.19
- Average True Range (ATR)
- INSI 0.20
- FENC 0.29
- MACD
- INSI -0.03
- FENC -0.01
- Stochastic Oscillator
- INSI 38.53
- FENC 85.71
About INSI Insight Select Income Fund
Insight Select Income Fund is a diversified closed-end, management investment company. The fund's investment objective is to seek a high rate of return, primarily from interest income and trading activity, from a portfolio principally consisting of debt securities. It offers various solutions such as risk management, liquidity management, and return generation among others.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.